01—Abstract
Summary
Summary of the 10-K filed February 22, 2012. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported net income of $75.7 milliona for fiscal 2011, compared with a net loss of $92.3 million in 2010, driven mainly by accelerated license revenue from the early termination of its Bristol-Myers Squibb collaboration on XL281 (effective October 8, 2011) and the wind-down of its Sanofi PI3K discovery collaboration (terminated December 22, 2011).
Total revenues rose to $289.6 millionb from $185.0 million, with license revenues of $245.5 million. The company stated it expects further net losses and negative operating cash flow for the foreseeable future, and that cash used in operations was $159.2 million in 2011. Management attributes the company's future to cabozantinib (XL184), its sole focus, which is in a Phase 3 trial for medullary thyroid cancer (EXAM trial met its primary endpoint, with progression-free survival of 11.2 months versus 4.0 months on placebo) and a rolling NDA was initiated in December 2011, with completion expected in the first half of 2012.
Two Phase 3 prostate cancer trials are planned or underway (COMET-2 initiated December 2011; COMET-1 expected in the first half of 2012). The balance sheet at December 31, 2011 showed $283.7 millionc in cash, marketable securities and long-term investments, including about $85.3 million on deposit as collateral for a Silicon Valley Bank loan. Debt totaled $181.5 million, including $91.4 million of Deerfield secured convertible notes and an $80.0 million Silicon Valley Bank term loan.
In February 2012, the company raised approximately $65 milliond in net proceeds from a public offering, and it states that current resources plus expected collaborator funding and offering proceeds will sustain operations for at least 12 months. An accumulated deficit of $1.1 billion remains, and stockholders' equity was $90.6 million. Key risks include the FDA's refusal to reach a Special Protocol Assessment agreement on the COMET-2 design, dependence on cabozantinib's success, reliance on a small number of collaborators (Bristol-Myers Squibb 59% and Sanofi 39% of 2011 revenues), and covenants in the Deerfield and Silicon Valley Bank agreements that require minimum cash balances.
02—Key points
Key Highlights
- Net income of $75.7 million for 2011, versus a net loss of $92.3 million in 2010, driven by accelerated license revenue of $99.1 million from the Bristol-Myers Squibb XL281 termination and $53.1 million from the Sanofi termination.
- Total revenues of $289.6 million in 2011, up from $185.0 million in 2010; Bristol-Myers Squibb accounted for 59% and Sanofi for 39% of 2011 revenues.
- Cabozantinib EXAM Phase 3 trial in medullary thyroid cancer met its primary endpoint: median progression-free survival of 11.2 months versus 4.0 months on placebo (hazard ratio 0.28); rolling NDA initiated December 2011, with completion expected in the first half of 2012 and potential approval by end of 2012 if priority review is granted.
- COMET-2 Phase 3 prostate cancer trial with a bone pain endpoint initiated December 2011 after the company could not reach a SPA agreement with the FDA; COMET-1 with an overall survival endpoint planned for the first half of 2012.
- Cash, marketable securities and long-term investments of $283.7 million at December 31, 2011, including about $85.3 million pledged as collateral to Silicon Valley Bank; February 2012 public offering raised approximately $65 million in net proceeds.
- Debt of $181.5 million at year-end 2011, including $91.4 million of Deerfield secured convertible notes and an $80.0 million Silicon Valley Bank term loan; the company expects continued net losses and negative operating cash flow.
- Cash used in operating activities of $159.2 million in 2011, mainly reflecting a $244.5 million reduction in deferred revenue from accelerated recognition; accumulated deficit of $1.1 billion.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Exelixis kept $0.26.
- Revenue$289.6M100.0%
- Cost of revenue$-00.0%
- Gross profit$289.6M100.0%
- Operating costs−$200.1M69.1%
- Operating income$89.5M30.9%
- Interest, other & tax−$13.8M4.8%
- Net income$75.7M26.1%
Where FY2011 revenue went
$289.6M- R&D: $156.8M, 54% of revenue
- Net income: $75.7M, 26% of revenue
- Cost of revenue: $0, 0.0% of revenue
- SG&A: $33.1M, 11% of revenue
- Other operating costs: $10.1M, 3.5% of revenue
- Interest, other & tax: $13.8M, 4.8% of revenue
Kept 26% as net incomeCost of revenue $0 · 0.0%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 22, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $289.64M$185.04M | +56.5% |
| Cost of Revenue | $0— | — |
| Gross Profit | $289.64M— | — |
| R&D Expenses | $156.84M$210.68M | −25.6% |
| SG&A Expenses | $33.13M— | — |
| Operating Expenses | $200.10M$276.44M | −27.6% |
| Operating Income | $89.53M-$91.40M | +198.0% |
| Interest Expense | $16.26M$9.34M | +74.1% |
| Net Income | $75.70M-$92.33M | +182.0% |
| EPS (Basic) | $0.60$-0.85 | +170.6% |
| EPS (Diluted) | $0.58$-0.85 | +168.2% |
| Shares Outstanding (Basic) | 126.02M108.52M | +16.1% |
| Shares Outstanding (Diluted) | 130.48M108.52M | +20.2% |
05—Questions
Frequently Asked Questions
Why did Exelixis report net income in 2011 after years of losses?
Net income of $75.7 million was primarily due to the acceleration of deferred license revenue after Bristol-Myers Squibb terminated the XL281 collaboration effective October 8, 2011 (accelerating $99.1 million), and the December 2011 termination of the Sanofi PI3K discovery collaboration (accelerating $53.1 million). The company says it expects further net losses for the foreseeable future.
What is the main pipeline asset and what is its regulatory status?
The company is focusing exclusively on cabozantinib (XL184). In the EXAM trial for medullary thyroid cancer, the primary endpoint was met. A rolling NDA was started in December 2011 and was expected to be completed in the first half of 2012, with a potential commercial launch in the second half of 2012 assuming priority review. The FDA granted Fast Track designation and orphan drug designation for certain thyroid cancers.
Is Exelixis funded for the next year?
The company anticipates that its cash, marketable securities and long-term investments, expected collaborator funding, and about $65 million in net proceeds from the February 2012 offering will enable it to maintain operations for at least 12 months following the filing date. It also says that future capital requirements will be substantial and that it may need to raise additional capital sooner than anticipated.
What covenant risks could affect the company's debt obligations?
The Deerfield note purchase agreement is triggered by an event of default if cash and cash equivalents fall below $20.0 million as of December 28, 2012, subject to a cure period. The Silicon Valley Bank loan requires a deposit balance of 100% to 107% of the outstanding term loan and lines of credit, and failure to maintain it could let the bank accelerate the debt. The company says it may need additional funding to stay in compliance.
How concentrated is the company's revenue?
Revenue is highly concentrated. In 2011, Bristol-Myers Squibb accounted for 59% of revenues and Sanofi for 39%. The company states it has derived substantially all of its revenues from collaborative research and development agreements, and it has no approved products or product sales revenue to date.
06—Continue